Immunovant: Funding, Investors & Team (Oct 2026)
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
Immunovant has raised $275M across 2 funding rounds on record, the most recent a Post-IPO Equity of $75.0M announced in Oct 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immunovant Company Profile and Key Stats
Latest funding round on record: Oct 2022.
Immunovant Funding Rounds
Immunovant raised $200M in a Post-IPO Equity announced in Aug 2021.
1.2 years later, a Post-IPO Equity of $75.0M was announced in Oct 2022.
Immunovant Founders and Leadership Team
No contact details are on record for this team yet.
Immunovant Funding Compared to Other Biotechnology Startups
Immunovant's latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immunovant in Biotechnology and New York
Companies Similar to Immunovant
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Immunovant Funding FAQs
What does Immunovant do?
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
How much funding has Immunovant raised?
Immunovant has raised $275M across 2 rounds on record. The most recent is a Post-IPO Equity of $75.0M announced in Oct 2022.
When did Immunovant last raise funding?
Immunovant's most recent funding round on record is a Post-IPO Equity of $75.0M, announced in Oct 2022.
Who is the CEO of Immunovant?
Andy Deig is listed as CEO at Immunovant.
Where is Immunovant headquartered?
Immunovant is based in New York, United States.
How many employees does Immunovant have?
Immunovant is in the 101-250 employee band.
How does Immunovant's funding compare to other Biotechnology startups?
Immunovant's latest round of $75.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Immunovant Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immunovant is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.